ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
FDA Approves Two New Indications For Rituxan(R) In Patients With Non-Hodgkin's Lymphoma
Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved, after a Priority Review, two additional uses for Rituxan(R) (Rituximab) for patients with CD20-positive, B-cell
non-Hodgkin's lymphoma (NHL). One new indication for Rituxan is for
first-line treatment of previously-untreated patients with follicular NHL
in combination with CVP (cyclophosphamide, vincristine and prednisolone)
chemotherapy. The second new indication is for the treatment of low-grade
NHL in patients with stable disease or who achieve a partial or complete
response following first-line treatment with CVP chemotherapy.
"The goal of treating low-grade or follicular NHL, a chronic cancer
marked by multiple recurrences, is to delay disease progression for as long
as possible," said Howard Hochster, M.D., Professor of Medicine and
Clinical Pharmacology, New York University School of Medicine and Cancer
Institute. "These approvals enable doctors and patients to select among
different treatment options with Rituxan in the front-line setting. As we
demonstrated in the Eastern Cooperative Oncology Group trial, the use of
extended Rituxan dosing following induction CVP chemotherapy in patients
who reached stable disease or better has been shown to decrease the risk of
disease progression, relapse or death."
In February 2006, Rituxan in combination with CHOP (cyclophosphamide,
doxorubicin, vincristine and prednisone) or other anthracycline-based
chemotherapy was approved as first-line treatment for patients with diffuse
large B-cell lymphoma (DLBCL). Rituxan was approved in 1997 as a single
agent for patients with relapsed or refractory, low-grade or follicular
CD20- positive, B-cell NHL.
"Nearly 10 years after Rituxan's initial approval, these new
indications highlight the clinical benefit of Rituxan as part of first-line
therapy for the treatment of low-grade or follicular non-Hodgkin's
lymphoma, providing patients additional options to fight this chronic
disease," said Hal Barron M.D., Genentech senior vice president,
development and chief medical officer. "The approvals are the result of an
extraordinary collaboration between Biogen Idec, Genentech, the Eastern
Cooperative Oncology Group, clinical investigators, the FDA, and most
importantly, the patients who participated in the clinical trials."
"These approvals further illustrate our commitment to optimizing
treatment for patients with B-cell-related diseases," said Arturo Molina,
M.D., Biogen.
Idec's Senior Director, Hematology/Oncology, Medical Research/Clinical
Development.
Clinical Studies
The FDA approval of Rituxan as a first-line treatment in previously-
untreated patients with follicular, CD20-positive, B-cell NHL in
combination with CVP chemotherapy is based on data from a Phase III,
randomized, controlled study of 322 patients. The study evaluated the
first-line use of Rituxan in combination with CVP chemotherapy (R-CVP)
versus CVP chemotherapy alone. All patients received up to eight three-week
cycles of CVP chemotherapy. Patients in the R-CVP arm received Rituxan 375
mg/m2 on Day 1 of each treatment cycle.
-- R-CVP improved median progression-free survival to 2.4 years from
1.4 years for CVP chemotherapy alone.
-- R-CVP reduced the risk of disease progression, relapse or death by
56 percent compared to CVP chemotherapy alone (hazard ratio = 0.44
p
FDA aprobã douã noi Indicaþii pentru Rituxan (R), la pacienþii cu non-Hodgkin's Lymphoma - FDA Approves Two New Indications For Rituxan(R) In Patients With Non-Hodgkin's Lymphoma - articole medicale engleza - startsanatate